Inhaled insulin: New technology, new possibilities

International Journal of Clinical Practice

Volumn 60, Issue 6, 2006, Pages 728-734

  Bellary, S ^a   Barnett, Anthony H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Diabetes mellitus; Exubera; Inhaled insulin

Indexed keywords

GLIBENCLAMIDE; INSULIN; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

AEROSOL; BODY WEIGHT DISORDER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COUGHING; DIABETES MELLITUS; DIET THERAPY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EXERCISE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LICENSING; LUNG DISEASE; MEDICAL TECHNOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; DIABETES MELLITUS; DRUG COSTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LUNG DISEASES; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33744524881     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00976.x     Document Type: Review

References (41)

1. American Diabetes Association: Clinical practice recommendations. 2000. Diabetes Care 2000; 23 Suppl 1: S1-116.
2. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
3. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of Insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-6.
4. Zamanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin treated diabetes. Diab Res Clin Pract 1999; 46: 239-46.
5. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997; 20: 292-8.
6. Gerber RA, Hauber AB, Bolinder B, Johnson FR. Diabetes patients' stated preference for insulin therapies: Trading health for convenience. Diabetologia 2004; 47 (Suppl. 1): A274.
7. Owens DR. New horizons - alternative routes for insulin therapy. Nat Rev Drug Discov 2002; 1: 529-40.
8. Chetty DJ, Chien YW. Novel methods of insulin delivery: An update. Crit Rev Ther Drug Carrier Syst 1998; 15: 629-70.
9. Byron PR. Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Adv Drug Deliv Rev 1990; 5: 107-32.
10. Klonoff DC. Inhaled insulin. Diabetes Technol Ther 1999; 1: 307-13.
11. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43: 781-801.
12. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14: 63-72.
13. Rave K, Bott S, Heinemann L et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28: 1077-82.
14. Himmelmann A, Jendle J, Mellen A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 2003; 26: 677-82.
15. Henry RR, Mudaliar SR, Howland WC 3rd et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003; 26: 764-9.
16. Becker RH, Sha S, Frick AD, Fountaine RJ. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006; 29: 277-82.
17. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005; 50: 1161-76.
18. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-7.
19. Skyler JS, Weinstock RS, Raskin P et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care 2005; 28: 1630-5.
20. Hollander PA, Blonde L, Rowe R et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-62.
21. Defronzo RA, Bergenstal RM, Cefalu WT et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28: 1922-8.
22. Rosenstock J. Zinman B, Murphy LJ et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2005; 143: 549-58.
23. Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: A 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004; 27: 162-7.
24. Rosenstock J, Baughman RA, Rivera-Schaub T et al. A randomised double blind, placebo controlled study of the efficacy and safety of Inhaled technosphere insulin in patients with type 2 diabetes. Diabetes 2005; 54 (Suppl.1): A88 [Abstract 357].
25. Garg S, Rosenstock J, Muchmore D, De La Pena A, Sun B, Silverman B. Safety and Efficacy of pre-prandial human insulin inhalation powder (HIIP) delivered by the Lilly/Alkermes inhaled insulin delivery system vs. injectable insulin in patients with type 1 diabetes. Diabetes 2005; 54 (Suppl. 1): A89 [Abstract 361].
26. Dumas R, England RD, Reise RJ, Teeter JG. Exubera is well tolerated and achieves tight glycemic control in patients with type 1 diabetes. Diabetes 2005; 54 (Suppl. 1): A87.
27. Barnett AH, Amiel SA, Hopkins D. Six month efficacy and 2-year safety of inhaled insulin as adjunctive therapy in combination with an oral agent. Diabet Med 2005; 22 (Suppl. 2): P82.
28. Dreyer M; for the Inhaled Insulin Phase 3 Study Group. Efficacy and 2 year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral monotherapy. Diabetologia 2004; 47 (Suppl. 1): A44.
29. Skyler JS; for the Inhaled Insulin Phase 2 Study Group. Long term sustained efficacy and safety of inhaled insulin after 4 years of continuous therapy. Diabetologia 2004; 47 (Suppl. 1): A311.
30. Petersen AH, Laursen T, Clauson P, Wollmer P. Absorption of inhaled insulin dramatically increases by large tidal volume ventilation in rabbits. Diabetes 2005; 54 (Suppl. 1): A101 [Abstract 401].
31. Henry RR, Mudaliar S, Chu N et al. Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: A pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol 2003; 43: 1228-34.
32. McElduff A, Mather LE, Kam PC, Clauson P. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. Br J Clin Pharmacol 2005; 59: 546-51.
33. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005; 90: 3287-94.
34. Heise T, Bott S, Tusek C et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: A prospective randomized pharmacodynamic study. Diabetes Care 2005; 28: 2161-9.
35. Bilous R. Overall satisfaction increased more with inhaled insulin than with subcutaneous insulin in type 1 diabetes. ACP J Club 2002; 136: 101.
36. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27: 1318-23.
37. Freemantle N, Blonde L, Duhot D et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28: 427-8.
38. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: A randomized controlled trial. Diabetes Care 2001; 24: 1556-9.
39. Testa MA, Turner RR, Hayes JF, Scranton RE, Simonson DC. An international trial of sulfonylurea plus either metformin or inhaled insulin: Impact on quality of life and treatment satisfaction. Diabetologia 2004; 47 (Suppl. 1): A5.
40. Simonson DC, Turner RR, Hayes JF, Scranton RE, Testa MA. Improving quality of life in type 2 diabetes when inhaled insulin is added after failure on metformin: A multicenter, international trial. Diabetologia 2004; 47 (Suppl. 1): A311.
41. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002; 24: 552-64.